Yedida Y Bogachkov PhD,  —

Yedida Y. Bogachkov is a science writer for BioNews. She holds a PhD in cellular and molecular pharmacology from the University of Illinois at Chicago. Prior to joining BioNews, she was conducting scientific research analyzing cancer genomics. She’s a Chicago native and hasn’t moved out of her hometown. Yes, she actually likes snow and enjoys having all four seasons. Yedida likes being out in nature, and in her free time, she can be found outside enjoying the fresh air or baking (inside). She is, unsuccessfully, trying to persuade the rest of her family to enjoy hiking. Yedida is excited to bring her passion for science and her desire to help people to BioNews.

Articles by Yedida Y Bogachkov PhD

Soleo Health Selected as US Distributor for Vyvgart for gMG

Soleo Health, a pharmacy specializing in infusion therapies, will serve as the U.S. distributor that will administer Vyvgart (efgartigimod), the newly approved treatment for people with generalized myasthenia gravis (gMG). Argenx, the therapy’s developer, selected Soleo Health as a limited distribution partner for Vyvgart, which was approved…

Merck Acquiring Cladribine as Potential Generalized MG Treatment

Merck KGaA has acquired Chord Therapeutics and the rights to continue developing CRD1 (cladribine), Chord’s lead candidate for treatment of generalized myasthenia gravis. “I am particularly pleased that Chord’s focus on severe, rare neurological conditions will be complemented by Merck’s established leadership with cladribine,” Arthur Roach, founder and…